341 related articles for article (PubMed ID: 32251204)
1. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease.
Chaparro M; Guerra I; Iborra M; Cabriada JL; Bujanda L; Taxonera C; García-Sánchez V; Marín-Jiménez I; Barreiro-de Acosta M; Vera I; Martín-Arranz MD; Hernández-Breijo B; Mesonero F; Sempere L; Gomollón F; Hinojosa J; Bermejo F; Beltrán B; Rodríguez Pescador A; Banales JM; Olivares D; Aguilar-Melero P; Menchén L; Ferreiro-Iglesias R; Blazquez Gomez I; Benítez García B; Guijarro LG; Marin A; Bernardo D; Gisbert JP;
Eur J Gastroenterol Hepatol; 2020 May; 32(5):588-596. PubMed ID: 32251204
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
3. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
Chanchlani N; Lin S; Bewshea C; Hamilton B; Thomas A; Smith R; Roberts C; Bishara M; Nice R; Lees CW; Sebastian S; Irving PM; Russell RK; McDonald TJ; Goodhand JR; Ahmad T; Kennedy NA;
Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):521-538. PubMed ID: 38640937
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
[TBL] [Abstract][Full Text] [Related]
6. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
7. Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease.
Yoshihara T; Shinzaki S; Kawai S; Fujii H; Iwatani S; Yamaguchi T; Araki M; Hiyama S; Inoue T; Hayashi Y; Watabe K; Iijima H; Takehara T
Inflamm Bowel Dis; 2017 Dec; 23(12):2172-2179. PubMed ID: 28945638
[TBL] [Abstract][Full Text] [Related]
8. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
Zapater P; Almenara S; Gutiérrez A; Sempere L; García M; Laveda R; Martínez A; Scharl M; Cameo JI; Linares R; González-Navajas JM; Wiest R; Rogler G; Francés R
Inflamm Bowel Dis; 2019 Jul; 25(8):1357-1366. PubMed ID: 30776076
[TBL] [Abstract][Full Text] [Related]
9. Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn's disease.
Yamamoto K; Chiba T; Matsumoto T
World J Gastroenterol; 2015 Sep; 21(35):10208-14. PubMed ID: 26401086
[TBL] [Abstract][Full Text] [Related]
10. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
Verstockt B; Moors G; Bian S; Van Stappen T; Van Assche G; Vermeire S; Gils A; Ferrante M
Aliment Pharmacol Ther; 2018 Oct; 48(7):731-739. PubMed ID: 30109889
[TBL] [Abstract][Full Text] [Related]
11. Effect of a concomitant elemental diet with maintenance anti-tumor necrosis factor-α antibody therapy in patients with Crohn's disease: A multicenter, prospective cohort study.
Hirai F; Ishida T; Takeshima F; Yamamoto S; Yoshikawa I; Ashizuka S; Inatsu H; Mitsuyama K; Sou S; Iwakiri R; Nozaki R; Ohi H; Esaki M; Iida M; Matsui T;
J Gastroenterol Hepatol; 2019 Jan; 34(1):132-139. PubMed ID: 29935082
[TBL] [Abstract][Full Text] [Related]
12. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn's disease.
Buisson A; Hordonneau C; Goutte M; Scanzi J; Goutorbe F; Klotz T; Boyer L; Pereira B; Bommelaer G
Dig Liver Dis; 2016 Mar; 48(3):260-6. PubMed ID: 26699828
[TBL] [Abstract][Full Text] [Related]
13. Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
Chiu YL; Rubin DT; Vermeire S; Louis E; Robinson AM; Lomax KG; Pollack PF; Paulson SK
Inflamm Bowel Dis; 2013 May; 19(6):1112-22. PubMed ID: 23584130
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of early restoration of quality of life in Crohn's disease patients receiving antitumor necrosis factor agents.
Herrera-deGuise C; Casellas F; Robles V; Navarro E; Borruel N
J Gastroenterol Hepatol; 2015 Feb; 30(2):286-91. PubMed ID: 25302652
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
[TBL] [Abstract][Full Text] [Related]
17. Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study.
van Haaften WT; Mortensen JH; Dige AK; Grønbæk H; Hvas CL; Bay-Jensen AC; Karsdal MA; Olinga P; Manon-Jensen T; Dijkstra G
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00217. PubMed ID: 33094957
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.
Watanabe M; Hibi T; Lomax KG; Paulson SK; Chao J; Alam MS; Camez A;
J Crohns Colitis; 2012 Mar; 6(2):160-73. PubMed ID: 22325170
[TBL] [Abstract][Full Text] [Related]
19. Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease.
Zittan E; Steinhart AH; Goldstein P; Milgrom R; Gralnek IM; Silverberg MS
Clin Transl Gastroenterol; 2021 Oct; 12(10):e00401. PubMed ID: 34613952
[TBL] [Abstract][Full Text] [Related]
20. Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas.
De Gregorio M; Lee T; Krishnaprasad K; Amos G; An YK; Bastian-Jordan M; Begun J; Borok N; Brown DJM; Cheung W; Connor SJ; Gerstenmaier J; Gilbert LE; Gilmore R; Gu B; Kutaiba N; Lee A; Mahy G; Srinivasan A; Thin L; Thompson AJ; Welman CJ; Yong EXZ; De Cruz P; van Langenberg D; Sparrow MP; Ding NS
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1306-1314. PubMed ID: 34389484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
